Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Ascletis Approved for China Phase IIb Test of HIV-Combination Treatment

publication date: Apr 13, 2020

Ascletis Pharma of Hangzhou reported its IND for a Phase IIb trial of its combination HIV candidate was approved in China. Ascletis says ASC09 offers a much higher genetic barrier to resistance than other protease inhibitors, requiring seven mutations before resistance develops. ASC09F is a fixed-dose combination of a protease inhibitor (ASC09) and a generic drug, ritonavir. Ritonavir is a generic antiretroviral often used in HIV-combinations. Ascletis acquired greater China rights for ASC09 from Janssen Pharma in 2013. More details....

Stock Symbol: (HK: 1672)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.